|

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

RECRUITINGPhase 1Sponsored by Stemline Therapeutics, Inc.
Actively Recruiting
PhasePhase 1
SponsorStemline Therapeutics, Inc.
Started2025-11
Est. completion2027-12-02
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07226427

Summary

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Key Inclusion Criteria:

* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Key Exclusion Criteria:

* Participants with primary platinum-refractory disease.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Conditions2

CancerPlatinum-resistant Ovarian Cancer

Locations1 site

NEXT Virginia
Fairfax, Virginia, 22031

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.